Doxorubicin exerts cytotoxic effects through cell cycle arrest and fas-mediated cell death

Pharmacology

Volumn 84, Issue 5, 2009, Pages 300-309

  Kim, Hye Sun ^a   Lee, Yong Soo ^a   Kim, Dong Ku ^a  

^a CHA University   (South Korea)

Author keywords

Apoptosis; Cell cycle arrest; Doxorubicin; Fas signaling; Murine lymphocytes

Indexed keywords

COMPLEMENTARY DNA; DOXORUBICIN; FAS ANTIGEN; MESSENGER RNA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD95; APOPTOSIS; CASPASES; CELL CYCLE; CELL ENLARGEMENT; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; FAS LIGAND PROTEIN; LYMPHOCYTES; MICE;

EID: 70349890757     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000245937     Document Type: Article

References (26)

1. Ueno M, Kakinuma Y, Yuhki K, Murakoshi N, Iemitsu M, Miyauchi T, Yamaguchi I: Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci 2006; 101: 151-158.
2. Lee SM, Youn B, Kim CS, Kim CS, Kang C, Kim J: Gamma-irradiation and doxorubicin treatment of normal human cells cause cell cycle arrest via different pathways. Mol Cells 2005; 20: 331-338.
3. Wu XX, Ogawa O, Kakehi Y: TRAIL and chemotherapeutic drugs in cancer therapy. Vitam Horm 2004; 67: 365-383.
4. Yoshimoto Y, Kawada M, Ikeda D, Ishizuka M: Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo. Int Immunopharmacol 2005; 5: 281-288.
5. Bellarosa D, Ciucci A, Bullo A, Nardelli F, Manzini S, Maggi CA, Goso C: Apoptotic events in a human ovarian cancer cell line exposed to anthracyclines. J Pharmacol Exp Ther 2001; 296: 276-2836
6. Green D, Kroemer G: The central executioner of apoptosis: caspases or mitochondria? Trends Cell Biol 1998; 8: 267-271.
7. Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM: Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 2006; 66: 4863-4871.
8. Gewirtz DA: A critical evaluation of the mechanism of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-741.
9. Wiernik PH, Dutcher JP: Clinical importance of anthracyclines in the treatment of acute myeloid leukemia. Leukemia 1992; 6: 67-69.
10. Czyz M, Szulawska A, Bednarek AK, Duchler M: Effects of anthracycline derivatives on human leukemia K562 cell growth and differentiation. Biochem Pharmacol 2005; 70: 1431-1442.
11. Dimanche-Boitrel MT, Meurette O, Rebillard A, Lacour S: Role of early plasma membrane events in chemotherapy-induced cell death. Drug Resist Updat 2005; 8: 5-14.
12. Poulaki V, Mitsiades CS, Mitsiades N: The role of Fas and FasL as mediators of anticancer chemotherapy. Drug Resist Updat 2001; 4: 233-242.
13. Jackson JG, Pereira-Smith OM: p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts. Cancer Res 2006; 66: 8356-8360.
14. Lai PB, Chi TY, Chen GG: Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro. Apoptosis 2007; 12: 387-393.
15. Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, O'Connor PM, Fornace AJ Jr, Harris CC: GADD45 induction of a G 2 /M cell cycle checkpoint. Proc Natl Acad Sci USA 1999; 96: 3706-3711.
16. White SJ, Kasman LM, Kelly MM, Lu P, Spruill L, McDermott PJ, Voelkel-Johnson C: Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free Radic Biol Med 2007; 43: 1313-1321.
17. Liebermann DA, Hoffman B: Gadd45 in the response of hematopoietic cells to genotoxic stress. Blood Cells Mol Dis 2007; 39:329-335. (Pubitemid 47484472)
18. Shimizu A, Nishida J, Ueoka Y, Kato K, Hachiya T, Kuriaki Y, Wake N: CyclinG contributes to G 2 /M arrest of cells in response to DNA damage. Biochem Biophys Res Commun 1998; 242: 529-533.
19. Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, Grevin C, McCabe N, McKenna S, White P, Song YH, Maheswarans S, Liu E, Haber DA, Johnston PG, Harkin DP: BRCA1 and GADD45 mediated G 2 /M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001; 20: 6123-6131.
20. Mariani M, Supino R: Morphological alterations induced by doxorubicin in B16 melanoma cells. Cancer Lett 1990; 51: 209-212.
21. Garmen S, Anel A, Lasierra P, Alava MA, Martinez-Lorenzo MJ, Pineiro A, Naval J: Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett 1997; 417: 360-364.
22. Malugin A, Kopeckova P, Kopecek J: HPMA copolymer-bound doxorubicin induces apoptosis in human ovarian carcinoma cells by a Fas-independent pathway. Mol Pharm 2004; 1: 174-182.
23. Wiernik PH, Dutcher JP: Clinical importance of anthracyclines in the treatment of acute myeloid leukemia. Leukemia 1992; 6: 67-69.
24. Song JH, Choi CH, Yeom HJ, Hwang SY, Kim TS: Monitoring the gene expression profiles of doxorubicin-resistant acute myelocytic leukemia cells by DNA microarray analysis. Life Sci 2006; 79: 193-202.
25. Friesen C, Herr I, Krammer PH, Debatin KM: Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1997; 2: 574-577.
26. Garmen S, Anel A, Lasierra P, Alava MA, Martinez-Lorenzo MJ, Pineiro A, Naval J: Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett 1997; 417: 360-364.